- McKesson boosted its fiscal 2023 adjusted diluted EPS outlook following strong FQ1 2023 operating performance.
- The whole drug distributor now sees FY2023 adj. diluted EPS of $23.95 to $24.65, up from $22.90 to $23.60. The consensus is $23.33. The company said that much of the increase is due to the U.S. government's COVID-19 vaccine, ancillary supplies, and COVID tests distribuition programs.
- McKesson's ( NYSE: MCK ) FQ1 results beat on the top and bottom lines .
- Net income of $809M in the quarter was a 52% increase from FQ1 2022.
- Revenue of $67.2B was a 7% year-over-year increase.
- Revenue in its largest segment, U.S. pharmaceutical, increased 14% to $56.9B.
- McKesson ( MCK ) ended the quarter with ~$2.2B in cash, a ~37% decline from Dec. 31, 2021.
- Seeking Alpha's Quant Ratings views McKesson ( MCK ) as a hold with strong grades for profitability, momentum, and revisions .
For further details see:
McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results